Climb Bio Stock Up After FDA Fast-Track Nod BTIG reiterated Buy on Apr 7, 2026 after Climb Bio received FDA Fast Track designation in early April 2026; regulatory acceleration alters timelines and investor expectations.

Climb Bio Stock Up After FDA Fast-Track Nod: BTIG reiterated Buy on Apr 7, 2026 after Climb Bio received FDA Fast Track designation in early April 2026; regulatory acceleration alters timelines and investor… 👈 Read full analysis #ClimbBio #FDANews #BiotechInvesting #StockMarket #Investing

BioXcel Therapeutics: FDA Accepts IGALMI Application FDA accepted BioXcel's IGALMI filing on Apr 1, 2026; review enters a 6–10 month window per FDA timelines and creates defined near-term catalysts.

BioXcel Therapeutics: FDA Accepts IGALMI Application: FDA accepted BioXcel's IGALMI filing on Apr 1, 2026; review enters a 6–10 month window per FDA timelines and creates defined near-term catalysts. 👈 Read full analysis #BioXcelTherapeutics #IGALMI #FDANews #Pharmaceuticals #DrugApproval

🚨 #BREAKING: The @fda.gov has approved Denalitx's Tividenofusp alfa-eknm (AVLAYAH)❗

The drug is indicated for treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II [ #MPSII ]) in pediatric patients.

#FDA #FDANews #DrugApproval #Neurology #Wow

🚨 BREAKING NEWS 🚨: @fda.gov Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC

Here's what you should know about the decision: www.onclive.com/view/fda-app...

#oncology #fdanews

FDA’s Fast-Track Voucher Surge: How 6 New Awards Instantly Impact the Drug Approval Race The FDA just issued six more fast-track review vouchers, instantly accelerating drug approvals for 15 companies and sending shockwaves through pharmaceutical innovation, investment decision-making, and patient access to game-changing therapies.The Fast-Track Voucher: A Critical Catalyst for Innovati

Six new FDA fast-track vouchers just changed the game for 15 pharma leaders. What does this surge mean for innovation, investment, and faster patient access? Full analysis at our site. #FDAnews #PharmaInsights

FDA’s Fast-Track Voucher Surge: How 6 New Awards Instantly Impact the Drug Approval Race The FDA just issued six more fast-track review vouchers, instantly accelerating drug approvals for 15 companies and sending shockwaves through pharmaceutical innovation, investment decision-making, and patient access to game-changing therapies.The Fast-Track Voucher: A Critical Catalyst for Innovati

Six new FDA fast-track vouchers just changed the landscape for drug approval. See which 15 companies gained an edge and what this means for biotech and patients on onlytrustedinfo.com. #FDAnews #DrugDevelopment

🚨 RFK Jr. orders FDA review of abortion pill 🚨 HHS Secretary Robert F. Kennedy Jr. says the FDA will re-examine mifepristone, widely used in medication abortions. Supporters call it safety, critics say politics. What’s your take? #RFKJr #Mifepristone #FDANews #ReproHealth

FDA to fast-track review of nicotine pouches from big tobacco firms - Reuters Investing.com-- The U.S. Food and Drug Administration is piloting a program to fast-track approval of nicotine pouches from four major tobacco companies, in a move that could reshape the booming market for smoke-free alternatives, Reuters reported on Monday, citing meeting transcripts. The FDA plans to complete reviews of products from Philip Morris International Inc (NYSE:PM), Altria (NYSE:MO), Reynolds American -- part of British American Tobacco (LON:BATS) -- and Turning Point Brands (NYSE:TPB) by December, far quicker than the years-long process companies have faced, Reuters reported. Earlier this year, the agency cleared 20 Philip Morris pouches under its Zyn label after a five-year wait. Products in the pilot include an updated version of Zyn, called Zyn Ultra, as well as Altria’s on! Plus, Reynolds’ Velo mini, and Turning Point’s Fre and Alp. For items already sold without FDA clearance, approval would remove legal risks and potential enforcement, the report said. The initiative comes amid pressure from the Trump administration to accelerate authorizations and follows heavy industry lobbying. Nicotine pouches, inserted under the lip, are the fastest-growing U.S. tobacco category, the report added. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for BATS plus thousands of other stocks and find your next hidden gem with massive upside.

Click Subscribe #FDANews #NicotinePouches #BigTobacco #TobaccoIndustry #PublicHealth

FDA Approves MMR IHC Panel pharmDx as a Companion Diagnostic for Nivolumab/Ipilimumab in MSI-H/dMMR CRC The FDA has greenlit the MMR IHC Panel pharmDx to determine eligibility for nivolumab/ipilimumab in patients with MSI-H/dMMR colorectal cancer.

.@fda.gov Approves MMR IHC Panel pharmDx as a Companion Diagnostic for Nivolumab/Ipilimumab in MSI-H/dMMR CRC
#ColorectalCancer #CRCSM #FDANews
www.onclive.com/view/fda-app...

FDA News HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.

The FDA has been busy in recent weeks! Catch up on all the headlines you may have missed by heading over to our FDA news resource center.

www.hcplive.com/clin...

#FDANews #Healthcare

Amphastar stock rises after FDA approves generic iron sucrose injection Investing.com -- Amphastar Pharmaceuticals (NASDAQ:AMPH) stock gained 4% after the company announced FDA approval for its generic version of iron sucrose injection, a treatment for iron deficiency anemia in patients with chronic kidney disease. The newly approved product, previously referred to as AMP-002, will be available in three dosage forms: 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials. Amphastar plans to launch the product in the third quarter of 2025. "We are delighted to announce the FDA approval of our generic iron sucrose injection," said Dr. Jack Zhang, Amphastar’s President and Chief Executive Officer. "This approval, once again, demonstrates our dedication to developing complex generics and leveraging cutting-edge, in-house manufacturing expertise to produce both active pharmaceutical ingredients and finished drug products under the highest regulatory standards in the U.S." The approval represents a significant opportunity for Amphastar, as the reference product Venofer® generated approximately $513 million in U.S. sales for the 12 months ended June 30, 2025, according to IQVIA data. Amphastar’s pipeline includes three ANDAs and one biosimilar insulin candidate currently under FDA review, targeting products with a combined market size exceeding $2.5 billion. The company is also developing three biosimilar products targeting a market exceeding $6 billion and two generic products aimed at a market of over $1 billion. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if AMPH is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #Amphastar #StockMarket #FDANews #IronSucrose #Pharmaceuticals

Popular sweetener recalled nationwide as FDA warns of label mix-up A pair of sweeteners are being recalled nationwide due to a labeling mishap, according to the Food and Drug Administration (FDA).

WHNT 19Alabama News Beacon #SweetenerRecall #FDANews #FoodSafety

On our YouTube page, we put out a poll asking what kind of video clinicians would like to see from us. Comment your answers below! New YouTube videos uploaded weekly. #Allergy #Dermatology #Rheumatology #Cardiology #Psychiatry #FDANews http://youtube.com/p

Innovation keeps accelerating—but so do the stakes.
Here are 7 high-impact FDA decisions to watch in H2 2025, from rare kidney disease to fibromyalgia.

www.hcplive.com/view...

#FDANews

Biggest news in healthcare from the first half of 2025?

Check out our list of 5 approvals to know from the first 6 months of 2025: www.hcplive.com/view...



#FDANews #Healthcare

OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025 Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025
@fda.gov #FDAnews
www.onclive.com/view/onclive...

Argenx stock falls after FDA flags serious risk signal with Vyvgart Investing.com -- Argenx NV ADR (NASDAQ:ARGX) stock tumbled 6% after the U.S. Food and Drug Administration (FDA) identified a potential serious risk associated with the company’s lead drug, Vyvgart. The FDA published a report highlighting a "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy" as a potential signal of serious risk with Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection. The regulatory agency stated it is currently evaluating the need for regulatory action. Vyvgart is Argenx’s flagship product, approved for treating generalized myasthenia gravis, a rare autoimmune disease. The identification of this safety concern comes at a critical time for the company, which has been positioning the medication as a key growth driver. The FDA regularly monitors approved drugs for potential safety issues that weren’t identified during clinical trials. When a potential signal is detected, the agency conducts further investigation to determine whether regulatory action is warranted, which could range from label updates to more significant restrictions. Investors reacted to the news by selling shares, reflecting concerns about potential impacts on Vyvgart’s commercial prospects should the FDA determine that additional warnings or limitations are necessary. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Argenx #Vyvgart #FDANews #StockMarket #Investing

🚨 BREAKING NEWS 🚨The @fda.gov Declines to Expand Label for Talazoparib/Enzalutamide in mCRPC
#PCSM #ProstateCancer #FDANews
Read up on the news:
www.onclive.com/view/fda-dec...

The FDA has accepted a New Drug Application for zoliflodacin, a single-dose oral antibiotic for uncomplicated #gonorrhea in patients aged at least 12 years. This would be the first new oral treatment option in decades. #FDANews

Read more: www.contemporaryobgyn.net/view/fda-acc...

The #FDA approved hydrocortisone (KHINDIVI) oral solution as a replacement therapy in pediatric patients aged 5 years and older with adrenocortical insufficiency, marking the first FDA-approved oral solution formulation of hydrocortisone.

🔗 www.hcplive.com/view...

#Endocrinology #FDANews

FDA Taps Vaxxer Skeptic Vinay Prasad To Oversee Vaccine, Gene Therapy Regulations - IndiaWest Journal News FDA Taps Vaxxer Skeptic Vinay Prasad To Oversee Vaccine, Gene Therapy Regulations.

FDA Taps Vaxxer Skeptic Vinay Prasad To Oversee Vaccine, Gene Therapy Regulations

Full Story: indiawest.com/fda-taps-vax...

#VinayPrasad #FDANews #VaccineRegulations #GeneTherapy #MedicalOversight #HealthPolicy #ControversialAppointment #ScienceDebate

The #FDA has approved 12.5 mg chlorthalidone tablets (HemiClor), targeted to lower blood pressure in the treatment of adults with hypertension, with expectations to be available in pharmacies nationwide beginning this month.

🔗 www.hcplive.com/view...

#Cardiology #FDANews

The @FDA delayed the target action date for the NDA for @Stealth BioTherapeutics elamipretide for the treatment of Barth syndrome. A revised action date has not yet been announced.

🔗 www.hcplive.com/view...

#FDANews

FDA to phase out dyes used in Flamin' Hot Cheetos, Skittles and other snacks

Hold onto your hats, snack lovers! The FDA is phasing out artificial dyes in some favorite treats like Flamin' Hot Cheetos and Skittles. 🤔 #FDANews #SnackFood #ArtificialDyes #FoodSafety

FDA News HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.

Catch up on the latest approvals and regulatory decisions from the FDA by heading over to our FDA News resource center: www.hcplive.com/clin...

#FDANews #FDA #Healthcare

FDA Announces Recall on Cat Food Over Bird Flu Risk Attention all pet parents!

While the disease primarily impacts birds, because the food is raw, pets that eat it could become infected. Owners who touch the food could be at risk if they handle the product & then touch their eyes, nose or mouth.

#Catfood #Recall #fdanews #catlovers #catlife #catlover #cats #safetyfirst

A new horizon in #FSGS coming soon?

Earlier this week, Travere Therapeutics announced plans to submit an sNDA for sparsentan (Filspari) based on DUPLEX trial and PARASOL data.

#Nephrology #FDANews

www.hcplive.com/view...

The #FDA has accepted the BLA for @LIBTherapeutics lerodalcibep targeting reductions in LDL-C in populations at high cardiovascular risk. A PDUFA date of December 12, 2025 has been set, with no plans to hold an advisory committee meeting.

🔗

#Cardiology #FDANews

FDA News Month in Review: January 2025 This FDA News Month in Review provides a round-up of regulatory decisions and submissions from January 2025.

Need a rundown of January's FDA decisions and submissions?

Check out our monthly FDA and pipeline news recap:

#FDANews

www.hcplive.com/view...